doi: 10.1016/j.neuropharm.2020.108042 242 WangZJHanYFZhaoFYangGZYuanLCaiHYet al
Evidence Full-length TB-4 has human clinical research across corneal, cardiac, and wound-repair programs, including clean Phase 1 safety data, plus dermal wound-healing models
its efficacy is comparable to oral diclofenac (Roth 2011)
Many patients also experience reduced appetite and modest weight loss, which can be beneficial for managing type 2 diabetes
Discontinuation typically results in weight regain, with patients recovering approximately two-thirds of lost weight within 12 months after stopping treatment
This helps you feel fuller longer, reduces cravings, and supports consistent weight loss when combined with healthy lifestyle changes